Voyager Therapeutics (NASDAQ:VYGR) was downgraded by investment analysts at Wedbush from an “outperform” rating to a “neutral” rating in a research note issued to investors on Monday, Marketbeat Ratings reports. They presently have a $29.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 19.54% from the company’s current price.
VYGR has been the subject of several other reports. Zacks Investment Research raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. Morgan Stanley raised their price objective on shares of Voyager Therapeutics from $36.00 to $39.00 and gave the stock an “overweight” rating in a report on Wednesday, February 21st. Canaccord Genuity reissued a “buy” rating and set a $26.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, January 23rd. BidaskClub raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Finally, BTIG Research began coverage on shares of Voyager Therapeutics in a report on Tuesday, December 19th. They set a “buy” rating and a $32.00 price objective for the company. Two research analysts have rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $29.20.
Voyager Therapeutics (VYGR) opened at $24.26 on Monday. The firm has a market cap of $590.34 and a price-to-earnings ratio of -8.54. Voyager Therapeutics has a fifty-two week low of $8.10 and a fifty-two week high of $31.91.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. MetLife Investment Advisors LLC acquired a new position in shares of Voyager Therapeutics in the 4th quarter valued at about $128,000. Iguana Healthcare Management LLC boosted its holdings in shares of Voyager Therapeutics by 100.0% in the 4th quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock valued at $830,000 after buying an additional 25,000 shares during the period. Millennium Management LLC acquired a new position in shares of Voyager Therapeutics in the 4th quarter valued at about $4,579,000. Teachers Advisors LLC boosted its holdings in shares of Voyager Therapeutics by 42.0% in the 4th quarter. Teachers Advisors LLC now owns 32,814 shares of the company’s stock valued at $545,000 after buying an additional 9,699 shares during the period. Finally, Ardsley Advisory Partners acquired a new position in shares of Voyager Therapeutics in the 4th quarter valued at about $415,000. 80.03% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3260568/voyager-therapeutics-vygr-lowered-to-neutral-at-wedbush.html.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.